Burges Salmon, the UK law firm, has played a key role in securing a £9 million funding package for Cumulus Oncology Limited, a cancer therapeutics company and Europe’s first oncology biotech creation studio.
THE funding, provided by the Scottish National Investment Bank and Eos Advisory, is aimed at advancing cancer research and accelerating the development of groundbreaking treatments. Cumulus Oncology, founded by Dr. Clare Wareing in 2017, focuses on areas of biology with robust scientific validation, paving the way for innovative therapeutic options for cancer patients. Burges Salmon’s Corporate and M&A team, led by senior associate Katie Carter, partnered with Cumulus Oncology since 2020, emphasising the law firm’s commitment to supporting scientific innovation and Scotland’s flourishing biotech capabilities.
Katie Carter, from Burges Salmon’s Corporate and M&A team, expressed admiration for Cumulus Oncology, stating, “We’ve been working with Cumulus Oncology since 2020, and it has been a pleasure to advise the team on this significant financing which supports the development of cancer research and shines a light on Scotland’s flourishing biotech capabilities.”
Clare Wareing, CEO of Cumulus Oncology, acknowledged the importance of the funding round, marking a milestone for the company. She expressed gratitude to Eos and the Scottish National Investment Bank for their support, enabling Cumulus Oncology to invest in existing projects and expand its portfolio of new biotechs, contributing to the advancement of cancer therapies. Wareing also commended the Burges Salmon team for their continued support and commitment.
Burges Salmon, celebrating its fifth anniversary in Edinburgh, has established a strong presence in the region, gaining a reputation for market-leading corporate practices in high-value and complex transactions. The law firm’s collaboration with Cumulus Oncology underscores its track record of working with pharmaceuticals, healthcare, life sciences, and biotech companies across the UK. The funding secured is expected to fuel Cumulus Oncology’s mission to develop the next generation of cancer therapies, further solidifying its position in the field of oncology research and treatment.
